This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
by Ahan Chakraborty
Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
RARENegative Net Change AMGNNegative Net Change DNLINegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
by Zacks Equity Research
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
SNDXNegative Net Change AMRNNegative Net Change CORTNegative Net Change ALDXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Reports Mixed Phase III Trial Results, Stock Down
by Zacks Equity Research
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
BMYNegative Net Change AMRNNegative Net Change CORTNegative Net Change CTNMNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?
MRNANegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
by Zacks Equity Research
TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
TGTXNegative Net Change ARVNNegative Net Change ETONNegative Net Change HOWLNegative Net Change
biotechs
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
by Zacks Equity Research
MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
MIRMNegative Net Change ARVNNegative Net Change ETONNegative Net Change HOWLNegative Net Change
biotechs
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
by Ahan Chakraborty
ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
ACADNegative Net Change AXSMNegative Net Change NGNENegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
by Ahan Chakraborty
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
by Zacks Equity Research
Roche advances vamikibart toward potential US approval after phase III trials show sustained vision improvements, reduced retreatment needs and a favorable safety profile.
RHHBYPositive Net Change BAYRYPositive Net Change CRSPNegative Net Change
biotechnology biotechs medical pharmaceuticals